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~70−90% within minutes when CK2 is inhibited by its speciﬁc inhibitor (TBB, n=8,
p< 0.001) but this WT inhibition disappears when a TBB-resistant CK2 mutant is
co-expressed with WT CFTR in oocytes (n=20, p< 0.001). Single channel analysis
shows similar results in mammalian cells where TBB CK2-inhibitor closes CFTR in
cell attached (but not detached) mode consistent with a protein–protein interaction in
cell attached (but not detached) patches. The missing link to inﬂammation manifests
when NFkB elevation in Hela cells stably expressing CFTR is found to be CK2
dependent in WT- but not DF508-CFTR expressing cell lines when exposed to Ps.
aeruginosa.
Conclusion: The data (Treharne et al 2007) are consistent with the idea that F508
is required for CK2 localisation to CFTR. A new collaboration funded by the
Italian CF Society with LA Pinna (Padua) is now shedding light on the mechanisms
involved leading to a new paradigm linking inﬂammation and ion transport in CF
due to malfunction of the CK2-DF508-CFTR interaction such that CK2 activity is
missing in the CF apical membrane.
Speculation: The ﬁnding that CFTR binds a known cancer inducing protein kinase
CK2 that targets another CFTR-bound cancer kinase (NDPK) whose function may
be abnormal in CF might explain the rising incidence of cancer in CF.
Supported by the Wellcome Trust, CF Trust and DFG.
R14 ROLE OF CFTR IN BILE SECRETION
M. Strazzabosco, C. Spirli, R. Fiorotto. Liver Center, Department of Internal
Medicine, Yale University School of Medicine, New Haven, CT, USA
In the liver, CFTR is selectively expressed by bile duct epithelium where it promotes
the transmembrane efﬂux of Cl− and bicarbonate. The biliary epithelium is the site
of rapid hormone-mediated regulation of the ﬂuidity and alkalinity of the primary
canalicular bile secreted by the hepatocytes. The net amount of ﬂuid and bicarbonate
secreted is determined by the integration of pro-secretory and anti-secretory signals.
Biliary epithelial cells (cholangiocytes) possess a polarized distribution of carriers
that mediate vectorial HCO−3 and ﬂuid secretion, under the endocrine control of
secretin/cAMP/PKA on the basolateral side and under the autocrine control of
extracellular ATP/P2Y-receptors/intracellular Ca2+ on the apical side. In cholangio-
cytes CFTR has multiple functions, including: (a) mediating cAMP-dependent Cl−
secretion in response to cAMP/PKA, (b) regulating the activity of the apical Na+/H+
and Cl−/HCO−3 exchangers, (c) modulating vesicle-mediated ﬂuid and electrolyte
transport, (d) facilitating the apical release of ATP. We have recently shown that
UDCA stimulates apical ATP secretion in a CFTR-dependent manner. Apical ATP,
thereby activating Ca2+-dependent Cl− channels, is then responsible for UDCA-
induced ductal choleresis. This is a novel mechanism with important implications
for the treatment of CF-related liver disease. In this regard it is important to consider
that CFTR-independent ﬂuid secretory pathways are also present in cholangiocytes.
We have recently shown that the sulphonylurea glibenclamide (GL) stimulates
vesicle-mediated secretion in bile ducts in a CFTR-independent manner. This effect
is maintained in CFTR-KO mice, in which GL is able to restores choleresis. Whether
these promising ﬁndings will be translated into CF treatment strategies is at present
unclear. The only liver-speciﬁc therapy for CF proposed to date is the use of ur-
sodeoxycholic acid (UDCA). Administration of UDCA slows the progression of the
disease in humans, however, the choleretic effect of UDCA on biliary cells depends
on its ability to stimulate a CFTR-dependent ATP secretion, suggesting that its
pharmacologic mechanisms in CF is different form stimulation of ductal choleresis.
R15 THE UK CF GENE THERAPY CONSORTIUM RESEARCH
PROGRAMME
U. Griesenbach. Imperial College London and the UK CF Gene Therapy
Consortium, United Kingdom
It has been suggested that modest increases in CFTR function (in the range of
5%) may be sufﬁcient to ameliorate lung disease severity. Although generally less
efﬁcient than viral vectors, we hypothesize that the transfection efﬁciency of the
best non-viral gene transfer agents may be sufﬁcient for clinical beneﬁt. In a large
pre-clinical study we have compared a number of non-viral gene transfer agents
and have chosen cationic lipid GL67 as our leading Wave 1 product. GL67 will
be complexed to a plasmid carrying the CFTR gene, which has been signiﬁcantly
improved compared to plasmids used in previous clinical trials. The plasmid has
been completely CpG-depleted to minimise inﬂammatory responses to the DNA and
importantly a promoter has been chosen that, at least in animal models, leads to
long-lasting (several weeks) gene expression. In our opinion, clinical beneﬁt of gene
therapy can only be assessed if gene expression is maintained over several months
and we are, therefore, preparing for a multi-dose clinical study designed to run for
12 months with monthly administration of GL67/DNA complexes or placebo (n = 50
subjects/group). Preparation for the multi-dose trial involves validation of novel
and established biomarkers as endpoint assays, identiﬁcation of criteria for patient
selection and importantly a single dose pilot trial to assess safety and duration
of gene expression in human. While the work-up for the clinical programme with
GL67 is moving forward, Consortium scientist are developing Wave 2 products in
an attempt to further improve gene transfer to the airway epithelium. Although most
viral vectors are not suitable for repeat dose clinical trials, lentiviral vectors are a
notable exception and may be suitable for CF gene therapy. Our pre-clinical data
using a F/HN-pseudotyped simian immunodeﬁciency virus-derived vector shows
that single administration leads to efﬁcient gene expression for up to 12 months
and, importantly, appears to be allow repeat administration. A summary of the pre-
clinical and clinical work currently carried out within the UK CF Gene Therapy
Consortium will be presented.
R16 NEW DRUGS TO CORRECT THE BASIC CF DEFECT
D.N. Sheppard. University of Bristol, Department of Physiology & Pharmacology,
School of Medical Science, Bristol, United Kingdom
Cystic ﬁbrosis (CF) is caused by mutations in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR), a Cl− channel with complex regulation that plays an
essential role in ﬂuid and electrolyte transport across epithelia. CFTR is assembled
from ﬁve domains: two membrane-spanning domains that form an anion-selective
pore, two nucleotide-binding domains (NBDs) that control channel gating and a
unique regulatory domain phosphorylation of which is a prerequisite for channel
activity.
By far the most common CF mutation is F508del, the deletion of a phenylalanine
residue at position 508 of the CFTR sequence. This mutation accounts for about
70% of CF mutations worldwide and is associated with a severe disease phenotype.
The F508del mutation disrupts the expression and function of CFTR in at least
three different ways. First and foremost, deletion of F508 causes misfolding of
CFTR protein, leading to the retention of the vast majority of the mutant protein
in the ER and its degradation by the proteasome. Second, decreased stability of
F508del-CFTR protein at the cell surface. Any F508del-CFTR that reaches the
apical membrane resides there for only a fraction of the time of wild-type CFTR.
Third, altered channel gating. F508del-CFTR Cl− channels exhibit a profound defect
in channel gating characterised by infrequent bursts of channel openings separated
by long closures of prolonged duration compared to those of wild-type CFTR.
Restoration of channel function to F508del-CFTR requires a drug to deliver the
mutant protein to the apical membrane (termed a CFTR corrector) and a drug to
rescue defective channel gating (termed a CFTR potentiator). A number of small
molecules have been identiﬁed (e.g. VRT-325 and Corr-4a) that rescue the cell
surface expression of F508del-CFTR [1,2]. Of note, VRT-325 and Corr-4a also
enhance the stability of F508del-CFTR at the apical membrane of CF epithelia [3].
A large number of small molecules have been identiﬁed (e.g. VRT-532), which act
as CFTR potentiators, rescuing the gating defect of F508del-CFTR [1]. Many of
these agents interact directly with the NBDs of CFTR to promote, and stabilise,
the formation of an NBD dimer, which controls channel gating. This presentation
will highlight how knowledge of the molecular pharmacology of CFTR is leading
to the development of new treatments for CF.
Reference(s)
[1] Van Goor F. et al. Am J Physiol (2006) 290, L1117–1130.
[2] Pedemonte N. et al. J Clin Invest (2005) 115, 2564–2571.
[3] Varga K. et al. Pediatr Pulmonol Suppl (2007) 30, 288.
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A. Mehta1, G. Mehta1, H. Olesen2, M. Macek3. 1Maternal and Child Health
Sciences, University of Dundee, United Kingdom; 2Pediatric Dept. Aarhus
University Hospital Skejby, Denmark; 3Institute of Biology and Medical Genetics,
Charles University Prague, Czech Republic
The European CF Registry project aims to unite cystic ﬁbrosis data collection
across continents. The project has received support from the European Commission
(Framework 6, EuroCareCF, work package 2) which runs from 2006−9. The core
objective is to create a common data structure between the United States and Europe
for use by European CF Centres and after the project is complete, it is planned to
use this structure to analyse the comparative demographics of CF. Our partners
include the Cystic Fibrosis Foundation of the United States who have supplied
their software (Port CF) for all participating European CF centres together with the
European CF Society (ECFS) who have supplied their data handling expertise and
logistic support. EuroCareCF work package 2 aims to provide solutions to the key
ethical, legal, practical, data protection and social hurdles that must be overcome
as described on our web site (www.eurocarecf.eu).
Methodology is described on the web site. Crucially, the design is such that a
CF centre based approach to collect the data maintains anonymity whilst enabling
countries to compile their own aggregate country speciﬁc reports with the express
consent of each CF Centre.
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Results: Thirty-nine countries have agreed to participate (original target 22) and
29 countries have sent their preliminary data. Initial analysis suggests a relative
paucity of CF patients in Europe who are over 35 years of age. Further analyses
are underway to determine the reasons.
Conclusions: The project is on track to meet its milestones despite an unexpected
rise in the take up from countries outside the European Union.
R18 OF MICE AND MEN: EARLY AIRWAY WALL DISEASE IN CYSTIC
FIBROSIS
A. Bush. Professor of Paediatric Respirology, Imperial College, London, United
Kingdom
The baby with cystic ﬁbrosis (CF) has essentially normal lungs at birth, but at
death has extensive airway wall destruction. This has been assumed to be secondary
to infection and inﬂammation, but recent evidence has challenged this paradigm,
and suggested that there may be a component of a speciﬁc CF related airway
wall disease, independent of infection and inﬂammation. We initially showed that
unscreened CF babies have airway obstruction at diagnosis, independent of any
previous or present respiratory symptoms, signs and positive cultures, and this
persists for six months, even despite intensive therapy [Lancet. 2001; 358:1964−5;
Am J Respir Crit Care Med. 2002; 166: 1350−7 & 2004; 169: 928−33]. Recent
data (Koslowska, unpublished) shows that even preschool children have CF related
airﬂow obstruction, independent of infection. We explored this using endobronchial
biopsy in CF children. We established the technique was safe [Pediatr Pulmonol.
2006; 41: 1021−4], and yielded acceptable material [Chest. 2007; 131: 1710−7];
we then showed that there were increased concentrations of elastin, glycosamino-
glycans and collagen in CF BALF compared to controls, and each correlated with
elastase activity, MMP-9 and neutrophil concentration. Both elastin concentration
and MMP-9:TIMP-1 ratio, correlated negatively with FEV1 (r = −0.45, p< 0.05
and r = −0.47, p< 0.05 respectively). Median reticular basement membrane (RBM)
thickness was greater in CF (5.9mm) than controls (4.0mm, p< 0.01), and corre-
lated with transforming growth factor-b1 (TGF-b1) concentration (r = 0.53, p = 0.01,
but not with FEV1. These data suggested there are two forms of airway remodelling
in CF children: ﬁrstly, matrix breakdown which correlates with proteases and pul-
monary function, and secondly RBM thickening, related to TGF-b1 concentration
[Hilliard T, Thorax in press]. We supplemented these observations in the CF mouse
nose [Hilliard T, Am J Resp Cell Mol Biol in press] by performing nasal lavage and
serial coronal section through the nasal tissue of adult CF and wild type mice raised
under normal housing conditions. Nasal tissue was also obtained from day 17 em-
bryos and newborn pups. Detailed histological examination of the nasal cavity was
performed. Bacterial culture, cell count and Macrophage Inﬂammatory Protein-2
(MIP-2) concentration were assessed in nasal lavage ﬂuid. Signiﬁcantly thickened
respiratory epithelium and increased mucous cell density was found in adult CF
mice of both mutations compared to wild type animals. There were no differences in
bacterial growth, cell count or MIP-2 concentrations. Thus, there are structural and
inﬂammatory changes in the nasal mucosa in adult CF mice, not present perinatally,
that develop in the absence of increased lumenal bacterial infection. Hence evidence
from both mice and men suggests there may be a CF-related airway wall disease,
independant of infection, which may represent a novel therapeutic target.
R19 PHARMACOGENOMICS IN CYSTIC FIBROSIS
L.J.V. Galietta. Istituto Giannina Gaslini, Genova, Italy
Pharmacotherapy of cystic ﬁbrosis (CF) basic defect, i.e. defective Cl− secretion,
requires a good knowledge of the loss of function mechanism associated with each
CF mutation. Indeed, CF mutations are typically grouped in ﬁve classes according to
the mechanism of action. Pharmacological approaches aimed directly at the CFTR
protein have been designed for three classes of mutations. For class I, consisting in
stop codon mutations, aminoglycoside antibiotics or the new agent PTC124 allow
to produce an almost normal CFTR by a read-through mechanism. For class II,
which includes F508del, pharmacological chaperones (also known as correctors)
can be used to improve the maturation of the mutant protein. Finally, class III
mutations, which cause a severe decrease in CFTR channel activity, can be treated
with potentiators, small molecules able to restore the normal channel gating.
The speciﬁc mechanism of each compound will clearly require in the future a
tailored use dependent on the CF patient genotype. However, the choice of a
particular pharmacological approach will not only depend on the CFTR genotype
but will need to consider also the inﬂuence of other genetic factors. For example,
the efﬁcacy of PTC124 and of other similar drugs affecting read-through of stop
codon mutations may be limited by nonsense-mediated mRNA decay, a process
that seems to be characterized by variability among individuals. On the other hand,
pharmacological chaperones identiﬁed so far for F508del probably interact with
cell proteins involved in CFTR biogenesis, intracellular transport, and degradation.
Accordingly, individual variability in CFTR protein handling due to genetic factors
may also affect the therapeutic outcome of F508del correctors.
Restoration of Cl− secretion in CF patients may be also obtained with the so-
called bypassing approach, i.e. by stimulating the activity of Ca2+-dependent Cl−
channels. Denufosol, a drug that is now tested in clinical studies, activates Ca2+-
dependent Cl− channels through interaction with the P2Y2 purinergic receptor. Also
in this case, individual variability may affect the extent of therapeutic intervention.
Indeed, it has been shown that polymorphisms in the P2Y2 receptor inﬂuence the
intracellular Ca2+ response triggered by purinergic agonists and therefore the extent
of Cl− secretion.
As for other human diseases, the inﬂuence of genetic variability will need to be
considered to optimize drug therapy in CF. This will be particularly important in
the design and evaluation of clinical studies testing the efﬁcacy of new drugs.
R20 FROM BENCH TO BEDSIDE: MODULATION OF AIRWAY
INFLAMMATION IN CYSTIC FIBROSIS
F. Ratjen. Division of Respiratory Medicine, The Hospital for Sick Children,
Toronto, Canada
Neutrophilic airway inﬂammation is a characteristic feature of cystic ﬁbrosis (CF)
lung disease. There is ongoing controversy whether the CFTR mutation itself causes
a pro-inﬂammatory milieu in the airways, which would imply that inﬂammation
can precede infection, or whether inﬂammation is always secondary to infection.
Studies in cell culture have yielded conﬂicting results. While initial studies showed
increased NFúB activation and IL-8 production in unstimulated CF epithelial cells,
others found a higher inﬂammatory response only after infection with P. aeruginosa.
Animal models of CF do not exhibit the phenotype of chronic infection, but
recent studies suggest that the response to infection is upregulated in CF mice.
Furthermore sterile CF airways transplanted into SCID mice demonstrate higher
IL-8 concentrations and luminal invasion of neutrophils, which would support the
concept of a pro-inﬂammatory milieu in CF. While it is important to clarify this,
there is sufﬁcient evidence that airway inﬂammation is present in almost all patients
with pulmonary manifestations of the disease. Since the presence of inﬂammation
has been shown to be a risk factor for subsequent lung function decline, reliable tests
to monitor airway inﬂammation in the clinic are urgently needed. Induced sputum
is currently being assessed as a clinical and research tool, but unfortunately is not
feasible in young children. While nonspeciﬁc treatment approaches that decrease
infection or improve clearance of airway secretions were found to positively affect
airway inﬂammation, speciﬁc anti-inﬂammatory treatment strategies have been less
successful to date. A number of studies have now provided evidence that potent
inhibitors of airway inﬂammation may potentially have a detrimental effect by
promoting airway infection. This stresses the need to develop a better understanding
of the factors regulating inﬂammation in the CF lung to develop better targeted
treatment strategies in the future.
R21 EXPLOITING GENOMICS TO DEVELOP NEW ANTIBIOTICS AND
VACCINES AGAINST CF-RELATED PATHOGENS
A. Bragonzi1, G. Do¨ring2. 1European Institute for Cystic Fibrosis Research,
Scientiﬁc Institute H.S. Raffaele, Milan, Italy; 2Institute of Medical Microbiology
and Hygiene, Universita¨tsklinikum Tu¨bingen, Tu¨bingen, Germany
Despite the development of potent antibiotics, P. aeruginosa and S. aureus still
cause most of the morbidity and mortality in patients with cystic ﬁbrosis (CF).
Multiple courses of antibiotics in these patients have increased the resistance of the
pathogens to many antibiotics and multi-resistant transmissible epidemic P. aerugi-
nosa and methicillin-resistant S. aureus (MRSA) strains have been identiﬁed in CF
centers. Sadly, the development of effective chemotherapeutic agents against these
pathogens has ceased in the last decade. Thus, alternative approaches to develop
antimicrobial agents with new modes of action and potent vaccines are needed.
Genome sequencing and advances in post-genomic technologies such as functional
genomics through antisense technology, insertion mutagenesis and bioinformatics
analysis has opened the way for large-scale screening of bacterial targets for new
antimicrobials. Integrated genomics, devised to screen whole bacterial genomes and
to identify targets, different from those identiﬁed using conventional approaches
can be used today. Using such techniques, key bacterial virulence determinants,
expressed under host/pathogen conditions, providing essential functions for bacterial
growth and pathogenesis in vivo, can be identiﬁed. To ensure broad protection,
sequence variability and adaptive mechanisms, leading to gene mutations and
homologous recombination have to be taken into account. Comparative genomic
analysis is now considered as critical to provide a solid rationale to further proceed
towards the development of antibacterials with global relevance.
